- Systematic Review
Background/Objectives: Medication-related osteonecrosis of the jaw (MRONJ) is a serious and detrimental condition affecting the jaw bones observed in patients receiving anti-resorptive therapy. The main aim of this systematic review was to identify the potential local risk factors and systemic co-morbidities that can contribute to the development of MRONJ. Methods: A systematic literature search was conducted in PubMed (via Ovid), Web of Science, and Scopus. Predefined inclusion and exclusion criteria were applied, and data were extracted from eligible studies on demographic characteristics, antiresorptive medications, underlying conditions, systemic comorbidities, local dental factors, anatomical distribution, and MRONJ stage. Results: Of 1899 records identified, 233 studies published between 2005 and 2024 met the eligibility criteria. Across these studies, 43,061 patients with MRONJ were reported, predominantly from developed countries. The mean age was 67.2 years (SD, 9.9), and 27,202 (63.2%) were female. Zoledronic acid was the most frequently reported antiresorptive medication (18,656; 43.2%), followed by pamidronate (6133; 14.2%) and denosumab (1923; 4.5%). Cancer was the most frequently reported underlying condition (19,237; 44.6%), followed by osteoporosis/osteopenia (10,806; 25.1%). Among cancer types, breast cancer (6286; 14.5%), multiple myeloma (4112; 9.5%), prostate cancer (3473; 8.1%), and oral cancer (2020; 4.6%) were the most frequently reported. Reported systemic comorbidities included hypertension (3188; 53.6%), chemotherapy (1562; 48.0%), smoking (936; 25.4%), anaemia (1066; 21.8%), diabetes mellitus (964; 19.6%), alcohol consumption (322; 19.2%), and rheumatoid arthritis (563; 9.5%), while radiotherapy was reported in 137 patients (38.0%) across six studies. Reported local dental factors included tooth extraction (5029; 47%), periodontal disease (3381; 46%), periapical infection (189; 37%), denture use (1728; 21.8%), dental abscess (50; 16.5%), dental caries (113; 15.9%), and dental implants (597; 15.4%). MRONJ lesions mostly involved the mandible (8952; 65.4%). Stage 2 MRONJ was most frequently reported (6620; 58.8%), followed by Stage 1 (2483; 22.0%) and Stage 3 (2037; 18.0%). Conclusions: This study provides a comprehensive overview of the related potential risks factors and co-morbid conditions associated with MRONJ. MRONJ predominantly affected older females, with cancer and osteoporosis/osteopenia requiring tooth removal. Zoledronic acid was the most commonly reported antiresorptive medication, while the mandible and Stage 2 MRONJ were most frequently reported. Further high-quality studies are needed to clarify the relative importance of individual risk factors to better guide prevention and management strategies in at-risk patients.
22 November 2026


![PRISMA flow chart of literature search [20].](https://mdpi-res.com/dentistry/dentistry-14-00764/article_deploy/html/images/dentistry-14-00764-g001-550.jpg)


![Flowchart of article selection process, adapted from PRISMA 2000 flow diagram [21].](https://mdpi-res.com/dentistry/dentistry-14-00761/article_deploy/html/images/dentistry-14-00761-ag-550.jpg)

